Clinical Trial Update: A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating SHR-A1811 as a neoadjuvant treatment for early-stage or locally advanced HER2-positive breast cancer, comparing it with other antitum…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• SHR-A1811

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Early-stage or Locally Advanced HER2-positive Breast Cancer | Phase 3 | Status: RECRUITING